Why the study?
Minor ischemic stroke is the most frequent presentation of cerebral vascular disease, and the study aimed to evaluate non-inferiority criteria comparing different antiplatelet regimens against aspirin as an active control.
Does antiplatelet therapy (dual therapy or other agents) reduce recurrent ischemic stroke in patients with minor ischemic stroke compared to aspirin alone?
Does antiplatelet therapy (dual therapy or other agents) reduce recurrent ischemic stroke in patients with minor ischemic stroke compared to aspirin alone?
Antiplatelet therapy (such as dual therapy or cilostazol) is clinically superior to aspirin alone for reducing recurrent ischemic stroke in patients with minor ischemic stroke, though dual therapy increases bleeding risk while cilostazol reduces it.
Supports alternatives to aspirin monotherapy in minor stroke; confirms clinical superiority rather than mere non-inferiority.
Minor ischemic stroke is the most frequent presentation of cerebral vascular disease and treatment with antiplatelet drugs can be used for the prevention of its recurrence. This systematic review and meta-analysis was aimed to assess non-inferiority criteria about the effect in the comparison of different antiplatelet schemes using aspirin as active control. Twelve randomized studies with a total of 52204 patients were chosen. All met the inclusion criteria with minor recurrent ischemic stroke as end point and any extracranial bleeding as safety event. The results showed a significant risk reduction of 22% [RR (95% CI) = 0.78 (0.72-0.84), p<0.0001, NNT: 67] in the recurrence of ischemic events with any antiplatelet drug (combined or not with aspirin) versus aspirin alone and there were no differences in the bleeding risk [RR (95% CI) = 1.02 (0.74- 1.41), p= 0.899, NNH: 500]. Dual antiplatelet therapy (DAPT) and cilostazol were more effective compared with aspirin alone (22% and 32% risk reduction respectively) but only cilostazol showed a higher reduction (52%) of bleeding events. In conclusion, although in some instances equivalence was demonstrated, a clinical superiority in the risk reduction for recurrent ischemic stroke of any antiplatelet treatment versus aspirin alone was observed. With the sole exception of the cilostazol trials there was an increase of the bleeding risk when the antiplatelet drugs treatments were compared with aspirin alone.
No takes yet. Share an insight, caveat, or question.
Vizcaíno et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: